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A record linkage was carried out between the Italian Registry of AIDS and 19 Cancer Registries (CRs), which covered 23% of the
Italian population, to estimate the overall cancer burden among persons with HIV or AIDS (PWHA) in Italy, according to various
characteristics. Observed and expected numbers of cancer and standardised incidence ratios (SIRs) were assessed until 1998 in
12104 PWHA aged 15–69 years, for a total of 60421 person-years. Significantly increased SIRs were observed for Kaposi’s sarcoma
(KS, 1749-fold higher than the general population), non-Hodgkin’s lymphomas (NHL, 352), and invasive cervical cancer (22). SIR was
significantly elevated also for cancer of the anus (34), lung cancer (2.4), brain tumours (4.4), Hodgkin’s disease (16), and leukaemias
(5.3). The majority of lung and brain cancers were not histologically confirmed, and the possibility of misclassification with KS or NHL
cannot be ruled out. The SIR for all non-AIDS-defining cancers was 2.2 in men and 2.5 in women. Intravenous drug users showed
significantly more elevated SIRs for lung cancer (9.4), and brain tumours (6.7) than other transmission categories (SIR¼1.4 and 2.3,
respectively). This study confirmed increased SIRs for haemolymphopoietic neoplasms other than NHL in PWHA, although many-
fold smaller than for NHL. An association with human papillomavirus-related cancers was also confirmed.
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Since the mid-1990s, cancer incidence in persons with HIV or
AIDS (PWHA) has been investigated by a few large population-
based linkage studies of AIDS and cancer registries (CRs) in the
United States (Goedert et al, 1998), Europe (Franceschi et al,
1998a), and Australia (Grulich et al, 2002). These studies have
provided essential information on the frequency and character-
istics of cancers in the course of HIV infection.
In comparison with the general population, PWHA show a
thousand-fold elevated risk of developing Kaposi’s sarcoma (KS)
and a hundred-fold higher risk of non-Hodgkin’s lymphoma
(NHL) (IARC, 1996; Dal Maso et al, 2001c) Increases have also
been reported for other cancer types, such as squamous
carcinomas of the anus, invasive cervical cancer (ICC), skin,
conjunctiva, and Hodgkin’s disease (Franceschi et al, 1998a; Frisch
et al, 2001; Grulich et al, 2002). Since most of these malignancies
are driven by oncogenic viruses, cancer excess in PWHA is likely
to be the combined effect of HIV and infections other than HIV
(Boshoff and Weiss, 2002). Excesses of neoplasms, such as cancer
of the lung, testis, and liver, have been reported less consistently
(IARC, 1996; Frisch et al, 2001). Finally, in all developed countries,
the introduction of the highly active antiretroviral therapies
(HAART) in the mid-1990s has greatly modified the natural
history of AIDS but, except for the decline in KS incidence, the
effect of HAART on cancer incidence in PWHA remains unclear
(International Collaboration on HIV and Cancer, 2000).
Italy offers an interesting research opportunity with respect to
such issues since the AIDS epidemic has grown faster, women
constitute a large proportion of PWHA (Dal Maso et al, 1995;
Pezzotti et al, 1999; ENAADS, 2000), and validated AIDS
surveillance programme covers the whole population while CRs
cover nearly a quarter of the population.
We have updated our previous study, including twice as many
person-years (Franceschi et al, 1998a). The purpose is to estimate
the cancer burden among PWHA in Italy overall and according to
time since AIDS and selected characteristics.
MATERIALS AND METHODS
The general design of our record linkage study has been described
previously (Franceschi et al, 1998a, b). In brief, notification of
AIDS cases from all over Italy to the AIDS Registry (RAIDS) in
Rome was initiated on a voluntary basis in 1982 and became
mandatory in November 1986. At the end of 2000, a total of 47503
AIDS cases had been reported (ISS, 2001). A linkage of RAIDS data
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AIDS cases in Italy was less than 10% (Conti et al, 1997), that is,
one of the lowest percentages of under-reporting in Europe
(Ajdacic-Gross et al, 2001).
In all, 19 independent CRs were active in Italy in the mid-1990s,
covering a population of 12.7 million, corresponding to 23% of the
total Italian population. They served the regions of Romagna,
Friuli-Venezia Giulia, Umbria, and part of Veneto region, the
municipality of Turin, the provinces of Genoa, Biella, Varese,
Parma, Modena, Ferrara, Macerata, Florence and Prato, Sassari,
Trento, Bolzano (Alto Adige), Ragusa, Latina, and part of the
province of Naples (Zanetti et al, 2002; Parkin et al, 2002). Cancer
Registeries varied both in size, ranging from approximately
190000 to nearly 1.9 million of population covered, and in number
of registration years available. Routine indicators of data
completeness and quality in Italian CRs were satisfactory (Parkin
et al, in press, 1997; Zanetti et al, 2002).
An ‘ad hoc’ software application was developed to perform the
record linkage procedure (Dal Maso et al, 2001c). Briefly, records
from RAIDS and CRs were linked by last and first name, and by
date of birth. Satisfaction of name–date algorithm required: (a)
that the records were identical for at least one critical field, and (b)
that the other two critical fields, if not identical, differed only in
prescribed ways. Since the system operated under procedures that
removed all personal identifiers, the staffs of each type of registry
were blinded to which persons had been linked.
The present study was restricted to people who: (1) were aged
between 15 and 69 years at the time of AIDS diagnosis; (2) reported
a legal residence in areas covered by CRs; (3) were diagnosed with
cancer in periods deemed complete at both registries (i.e. in most
instances through to the end of 1998); and (4) were diagnosed with
AIDS after 1985, since no cancer case among PWHA had been
reported earlier.
AIDS-defining cancers (i.e. KS, NHL and, since 1993, ICC) are
also reported to RAIDS, but only notification of neoplasms to CRs
were included in the present analysis for the sake of comparability
with non-AIDS defining cancers (NADC). In situ carcinoma of the
cervix and other preneoplastic lesions (e.g. behaviour code 0–2)
(WHO, 1990) were excluded from the present analysis because of
incomplete reporting in CRs.
Cancers at CRs were identified according to International
Classification of Diseases, 9th revision (WHO, 1977) and Interna-
tional Classification of Diseases for Oncology (ICDO) (WHO,
1990). Cases were subsequently recoded according to International
Classification of Disease, 10th revision (WHO, 1992). Cancers were
further subdivided according to whether histological, haematolo-
gical, or cytological confirmation (henceforth referred to as
histological confirmation) was available or diagnosis had been
made otherwise (i.e. clinical, instrumental diagnosis, etc.). Cancer
Registry coordinators reviewed all records on histological type and
site of cancers.
When an AIDS-defining cancer was mentioned in both RAIDS
and CR, date of cancer diagnosis was defined as the earliest one.
When KS, NHL, or ICC (after 1993) was reported in the CR up to 5
years prior to the date of AIDS diagnosis in RAIDS, the date of
AIDS onset was backdated.
Person-years at risk were computed only between 5 years prior
to AIDS diagnosis (in order to exclude cancer diagnosis which may
have occurred before HIV infection) and date of death or 3.5 years
after AIDS diagnosis, whichever occurred earlier, to reduce
inaccuracies from losses at follow-up. This interval was left- or
right-censored if no complete CR data were available in the
corresponding years. Expected numbers of different cancer sites or
types were computed in each CR from sex- and age-specific (5
years) incidence rates (Parkin et al, 2002, 1997, 1992) in four
periods: early pre-AIDS (from  60 to  25 months), late pre-AIDS
(from  24 to  7 months), AIDS period (from  6t oþ3 months),
and post-AIDS period (from þ4t oþ42 months). Observed
numbers of cancer in PWHA were compared to expected numbers
by means of standardised incidence ratios (SIRs). Corresponding
95% confidence intervals (CI) were computed using the Poisson
distribution (Breslow and Day, 1987).
RESULTS
Overall, 12104 AIDS cases (78% men and 22% women) were
reported in areas covered by one of the 19 CRs (Table 1) for a total
of 60421 person-years (Table 2). In all, 70% of person-years
referred to the periods prior to AIDS diagnosis. The majority of
PWHA enrolled in this study were intravenous drug users (IDUs,
62%), and the median age was 33 years. Between 5 years before
AIDS diagnosis and 3.5 years thereafter, 170 cancers other than KS,
NHL, and ICC were identified (Table 1). Using only cancer
information from CRs, the numbers were 525 for KS, 449 for NHL,
and 18 for ICC.
Table 2 shows observed and expected numbers and correspond-
ing SIRs for cancer sites or types with at least two cases observed.
As expected, high SIRs were found for KS (1749; 95% CI: 1602–
1905), NHL (352; 95% CI: 320–386), and, to a lesser extent, ICC
(22; 95% CI: 13–35). All ICC were squamous-cell carcinomas.
The combination of NADC showed a SIR of 2.3 (95% CI: 2.0–
2.7). Significantly elevated SIRs were seen for cancer of the anus
(34; 95% CI: 12–74), lung (2.4; 95% CI: 1.5–3.7), brain (4.4; 95%
CI: 2.2–8.0), Hodgkin’s disease (HD) (16; 95% CI: 12–22), and
leukaemias (5.3; 95% CI: 2.8–9.2). In respect to time of cancer
diagnosis, all sites and types showed the highest SIR in the AIDS
period and a compensatory fall in SIR after AIDS. Risk excess
before AIDS was seen for ICC and cancer of the anus, and for HD
and leukaemias.
Anal cancers (six cases) included five squamous-cell carcinomas
and one cloacogenic carcinoma.
Only 12 out of 22 lung cancers were histologically confirmed,
including five squamous-cell carcinoma, two adenocarcinoma, and
one each of five other histologies. In four out of 10 nonhistolo-
gically confirmed lung cancer cases, lung lesions of infectious
origin, such as pneumocystis carinii pneumonia, were reported at
RAIDS. None of the 11 brain cancers were histologically
confirmed, eight had occurred in the AIDS period, and three had
a concurrent diagnosis of cerebral toxoplasmosis or HIV
encephalopathy at RAIDS. The proportions of histologically
confirmed cancers among PWHA (79%) were similar to the
proportion in the general population of the same CRs (80%).
Restricting the analysis to cancers with histological confirmation,
the SIR was 1.7 (95% CI: 1.4–2.1) for the combination of all NADC.
The greater reduction in SIR, after the exclusion of unconfirmed
cases, was noted for cancer of the lung (SIR¼1.3) and brain
(SIR¼0.0) (not shown).
Among 45 HDs, the histological type was mixed cellularity in 19
subjects and nodular sclerosis in 13. The other HDs were of
lymphocytic predominance (one), lymphocytic depletion (three),
and unspecified type (nine).
The cancer sites or types that showed a significant excess in
PWHA or were observed in more than 10 individuals were re-
examined in separate strata of gender, age, and HIV-exposure
category (Table 3). Standardised incidence ratios were higher in
women than in men for KS (2717 vs 1696, respectively), NHL (538
vs 321), and cancer of the lung (8.7 vs 2.2). For the combination of
all NADS, no difference emerged between genders (SIR¼2.2 and
2.5 in men and women, respectively). The age distribution varied
by cancer type: median age was 37 years for KS (range: 19–68), 33
years for NHL (21–68), 35 years for ICC (37–48), 42 years for anal
cancer (34–55), 39 years for lung cancer (23–68), 50 years for
non-melanomatous skin cancer (36–69), 31 years for brain cancer
(28–58), 32 years for HD (19–43), and 32 years for leukaemias
(21–67). Standardised incidence ratios tended to be higher in the
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y15–34-year age group than in the 35–69-year age group for all
cancer sites, except for KS and cancers of the cervix uteri and anus.
Standardised incidence ratios were also higher among IDUs than
other HIV exposure category for all cancer types except for KS and
leukaemias. Standardised incidence ratio for KS and anal cancer
was particularly high among homosexual and bisexual men (6066
and 56, respectively).
The risk of NADCs in PWHA at or after AIDS diagnosis
(patients who were likely to take advantage of HAART) did not
diminish between pre-HAART (SIR¼4.7) and post-HAART
period (SIR¼5.7). Moreover, no statistically significant change
emerged for any specific cancer site or type of NADCs (data not
shown).
DISCUSSION
Cancers of the anus, brain, lung, HD, and leukaemias, in addition
to AIDS-defining cancers (KS, NHL, and ICC), have been found in
our study to be significantly increased in PWHA.
As in previous studies (Franceschi et al, 1998a; Sitas et al, 2000;
Grulich et al, 2002; Frisch et al, 2001), the group of NADCs, which
showed the most consistent excess in PWHA was lymphohaema-
topoietic cancers. HD risk, among PWHA, was more than 10-fold
increased in every strata of gender, age, and HIV-exposure
category. An association between HD and HIV infection is, hence,
well established (Dal Maso and Franceschi, 2003). An excess of
leukaemias and myeloma is also suggested by our present findings.
Histological confirmation was available for almost all HDs (43
out of 45), myelomas (three out of three), and leukaemias (10 out
of 13) in our study. A misdiagnosis of NHL as other haemolym-
phopoietic neoplasms cannot be totally ruled out because the
classification of haemolymphopoietic neoplasms in PWHA is
especially difficult (Carbone, 2002). Some leukaemias might be
leukaemoid transformations of AIDS-related NHL. The SIR for
lymphoid leukaemia was not significantly greater than the one for
myeloid leukaemia, in agreement with the findings by Frisch et al
(2001) in the United States.
As in previous reports (Andrieu et al, 1993; Serraino et al, 1993),
the most common subtype of HD in PWHA was mixed cellularity
type. Nodular sclerosis type (i.e. the commonest HD type in the
general population of an age comparable to PWHA) was relatively
rare. Besides being more aggressive and more frequently involving
bone marrow, HD in PWHA seems to be associated with EBV more
often than in the general population (Tirelli et al, 2000).
Other cancers whose SIRs were found to be consistently elevated
in PWHA are those associated with HPV infection (IARC, 1995). In
contrast to KS and NHL, ICC has been an AIDS defining disease
only since 1993 (Ancelle Park, 1993). We were, therefore, able to
observe some ICC cases prior to AIDS and noticed that, although
SIR peaked in the AIDS period as for all other sites and types, some
excess was present years before AIDS. A similar time pattern was
found for anal cancer, whose overall SIR (34) was well comparable
to the one seen for ICC. Three additional cases of cancer of the
vulva, penis, and uterus (not otherwise specified) further support
the possibility that HIV-induced immune impairment facilitates
the persistence of HPV infection (Palefsky et al, 1999; Ahdieh et al,
2000): progression into pre-malignant (Sun et al, 1997) and,
ultimately, in the lack of early detection, invasive cancer. As
suggested also by studies where preinvasive lesions of the cervix
and anogenital tract were included (Frisch et al, 2000), the control
of HPV infections seems to be impaired in HIV-positive women
and men years before a diagnosis of AIDS. Early events in HPV
carcinogenesis are probably affected to a greater extent than late
ones (i.e. invasiveness). The SIR for cancer of the cervix and anus
was marginally greater but not restricted to specific HIV exposure
categories (i.e. IDUs and homosexual and bisexual men, respec-
tively). Since HPV and HIV share a sexual route of transmission, it
has been considered difficult to disentangle their independent
contribution to the increase in risk of anogenital cancer in PWHA
(Mandelblatt et al, 1999). A majority of sexually active women
(Woodman et al, 2001) and men (Franceschi et al, 2002), however,
at some point in their lifetime are infected by HPV. Therefore,
factors that enhance the probability of HPV infection becoming
persistent and progress into premalignant and malignant lesions
are crucial (IARC 1995). In particular, a lack of cytotoxic T-
Table 1 AIDS diagnoses and linked cases by type of cancer in 19 Italian areas covered by Cancer Registries (CRs)
Population
AIDS cases
in CR areas
Linked cases
a
CR Complete period ( 1000) Cancer cases (1982–2000) KS NHL ICC Other cancers
Alto Adige 1995–97 453 8107 196 4 2 0 3
Biella 1995–98 190 5782 253 3 6 1 1
Ferrara 1989–98 361 32749 379 14 18 0 3
Florence 1985–97 1071 97506 1050 100 58 1 29
FVG 1995–98 1186 40002 379 6 4 0 1
Genoa 1985–96 679 76746 1566 59 51 4 22
Latina 1983–98 527 21630 337 5 9 1 1
Macerata 1991–97 358 12773 112 6 2 1 0
Modena 1988–98 620 42681 543 32 21 2 6
Naples 1996–98 525 4655 94 1 2 0 0
Parma 1982–98 391 27745 308 17 13 0 7
Ragusa 1982–97 313 16892 53 2 1 0 1
Romagna 1985–97 433 71553 1485 63 64 2 22
Sassari 1992–97 468 11883 302 7 12 0 3
Trento 1995–98 455 11756 284 5 8 0 4
Turin 1985–98 963 85751 1106 83 37 1 25
Umbria 1994–97 911 27745 372 14 19 0 4
Varese 1982–97 789 54400 1462 39 66 3 14
Veneto 1987–96 1890 121347 1823 65 56 2 23
Total 12583 698380 12104 525 449 18 170
KS¼Kaposi’s sarcoma; NHL¼non-Hodgkin lymphoma; ICC¼invasive cervical cancer; FVG¼Friuli-Venezia Giulia.
aCancers notified at CRs in people with AIDS, age 15–69 years, between 1985 and 1998 from 5 years prior to 3.5 years after an AIDS diagnosis.
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yTable 2 Observed (Obs) and expected (Exp) numbers of cancers in person HIV or with AIDS, SIR, and corresponding 95% CI by time of diagnosis and overall. Italy, 1985–1998
60–25 months
before AIDS
24–7 months
before AIDS
6 months before to
3 months after AIDS
a
4–42 months
after AIDS Total
ICD10, cancer type or site Obs SIR (95% CI) Obs SIR (95% CI) Obs SIR (95% CI) Obs SIR (95% CI) Obs Exp SIR (95% CI)
Person years 27882 14652 7491 10397 60421
C46, KS 406 6667 (6034–7348) 119 497 (412–595) 525 0.30 1749 (1602–1905)
C82–C85, NHL 322 1229 (1098–1371) 127 125 (105–149) 449 1.27 352 (320–386)
C53, ICC 1 3.0 (0.0–17.5) 2 9.6 (0.9–35.4) 14 121.2 (66–204) 1 5.8 (0.0–33.1) 18 0.82 21.8 (12.9–34.6)
C16, Stomach 1 0.6 (0.0–3.7) 1 1.1 (0.0–6.2) 4 8.1 (2.1–21.1) 2 3.3 (0.3–12.2) 8 3.56 2.2 (1.0–4.4)
C18, Colon 0 0 — 2 1.8 (0.2–6.6) 1 1.6 (0.0–9.4) 1 1.3 (0.0–7.5) 4 4.21 0.9 (0.2–2.5)
C20, Rectum 0 0 — 1 1.7 (0.0–10.0) 2 6.5 (0.6–23.9) 2 5.2 (0.5–19.0) 5 2.18 2.3 (0.7–5.4)
C21, Anus 3 44.4 (8.4–131.4) 0 0 — 1 38.5 (0.0–220.9) 2 51.5 (4.9–189.2) 6 0.18 33.6 (12.1–73.6)
C22, Liver 0 0 — 0 0 — 1 4.3 (0.0–24.6) 2 6.9 (0.7–25.5) 3 1.58 1.9 (0.4–5.6)
C25, Pancreas 0 0 — 0 0 — 1 5.5 (0.0–31.4) 1 4.4 (0.0–25.1) 2 1.27 1.6 (0.1–5.8)
C32, Larynx 0 0 — 0 0 — 1 3.7 (0.0–21.0) 1 3.0 (0.0–17.3) 2 1.95 1.0 (0.1–3.8)
C33–C34, Trachea and lung 1 0.3 (0.0–1.5) 0 0 — 13 10.3 (5.5–17.7) 8 5.4 (2.3–10.8) 22 9.02 2.4 (1.5–3.7)
C43, Melanoma 0 0 — 1 1.1 (0.0–6.1) 2 3.9 (0.4–14.3) 0 0 — 3 3.72 0.8 (0.2–2.4)
C44, Skin 3 0.8 (0.2–2.4) 5 2.1 (0.7–4.9) 3 2.3 (0.4–6.7) 3 1.7 (0.3–4.9) 14 9.28 1.5 (0.8–2.5)
C50, Breast
b 0 0 — 3 2.6 (0.5–7.8) 0 0 — 0 0 — 3 4.43 0.7 (0.1–2.0)
C56, Ovary 0 0 — 0 0 — 3 33.1 (6.2–98.1) 0 0 — 3 0.68 4.4 (0.8–13.2)
C61, Prostate 0 0 — 1 2.1 (0.0–11.8) 0 0 — 1 3.1 (0.0–17.6) 2 1.72 1.2 (0.1–4.3)
C62, Testis 0 0 — 4 4.3 (1.1–11.2) 0 0 — 0 0 — 4 3.73 1.1 (0.3–2.8)
C64, Kidney 1 0.9 (0.0–5.0) 1 1.4 (0.0–8.0) 1 2.6 (0.0–14.8) 0 0 — 3 2.75 1.1 (0.2–3.2)
C67, Bladder 0 0 — 1 0.8 (0.0–4.5) 0 0 — 1 1.2 (0.0–7.0) 2 4.80 0.4 (0.0–1.5)
C70–C72, Brain 0 0 — 0 0 — 8 24.3 (10.4–48.0) 3 6.6 (1.2–19.5) 11 2.48 4.4 (2.2–8.0)
C81, Hodgkin’s disease 6 4.6 (1.6–10.0) 12 17.9 (9.2–31.4) 19 56.3 (33.8–88.1) 8 17.6 (7.5–34.8) 45 2.77 16.2 (11.8–21.7)
C90, Myeloma 0 0 — 1 6.0 (0.0–34.5) 0 0 — 2 16.6 (1.6–61.0) 3 0.62 4.8 (0.9–14.3)
C91–C95, Leukaemia, all 1 0.9 (0.0–5.4) 3 4.9 (0.9–14.4) 6 18.5 (6.7–40.5) 3 6.9 (1.3–20.4) 13 2.44 5.3 (2.8–9.2)
C91, Leukaemia, lymphoid 1 2.7 (0.0–15.2) 0 0 — 4 34.0 (8.8–87.8) 0 0 — 5 0.87 5.7 (1.8–13.5)
C92, Leukaemia, myeloid 0 0 — 2 5.7 (0.5–21.0) 1 5.4 (0.0–30.9) 2 7.9 (0.7–29.2) 5 1.39 3.6 (1.1–8.4)
All non-AIDS defining cancer
c 18 0.6 (0.3–0.9) 39 2.0 (1.4–2.8) 68 6.6 (5.1–8.4) 45 3.3 (2.4–4.5) 170 74.48 2.3 (2.0–2.7)
SIR=Standardized Incidence Ratios; CI=Confidence Intervals; KS=Kaposi’s Sacroma; NHL=Non-Hodgkin Lymphoma; ICC=Invasive Cervical Cancer.
aFor KS and NHL: from AIDS to 3 months after.
bFemales only.
cIt includes
neoplasms excluding KS, NHL and ICC plus one of each: lip; nasopharynx; digestive organs, not otherwise specified; nasal cavity; mediastinum; connective tissue; retroperitoneum; vulva; corpus uteri; uterus, not otherwise specified;
penis; endocrine glands; and unknown primary site.
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Epidemiologylymphocyte to the early (E) oncoprotein six antigen is associated
with persistence of HPV infection (Tindle, 2002).
Nonmelanomatous skin cancer showed a three-fold excess in
PWHA in our previous report (Franceschi et al, 1998a), whereas a
somewhat lower SIR (1.5; 95% CI: 0.8–2.5) emerged from our
present update. Misclassification with KS seems unlikely, since all
nonmelanomatous skin cancers in PWHA were histologically
confirmed (seven squamous-cell and seven basal-cell carcinomas).
The report of nonmelanomatous skin cancer to CRs is, however,
incomplete (Levi et al, 1995; Parkin et al, 1997) and the
corresponding SIR must be interpreted cautiously. No data on
nonmelanomatous skin cancer are available from North American
(Frisch et al, 2001) and Australian (Grulich et al, 2002) record
linkage studies. Gallagher et al (2001) reported a 10-fold increased
SIR of cancer of the lip in New York State and several authors
(Frisch et al, 2001; Grulich et al, 2002) showed a two- to- four-fold
increased risk. Interestingly, skin cancer in our study affected
more frequently older PWHA than any other NADC.
Cancers of the lung and brain are found to be consistently
increased among PWHA, but masses of non-neoplastic origin or
attributable to NHL are common in the lung and brain at AIDS
diagnosis. These masses may be misdiagnosed as cancer of the
lung or brain, particularly in the absence of histological
confirmation. Interestingly, lung cancer showed the most marked
variation by HIV transmission group among NADCs. As in
Serraino et al (1997, 2000), lung cancer seemed restricted to IDUs,
among whom smoking levels are much higher than in the general
population.
Hepatocellular carcinoma is another cancer type aetiologically
related to viruses (i.e. hepatitis B and C viruses) that, in turn, share
the same route of transmission of HIV and have a high prevalence
in PWHA (Smukler and Ratner, 2002). However, our present study
showed only a moderate excess (SIR¼1.9) of HCC in agreement
with other authors (Frisch et al, 2001; Gallagher et al, 2001; Grulich
et al, 2002). It is possible that, until recently, PWHA have not
survived long enough to allow the carcinogenic effect of hepatitis
viruses to manifest (Deuffic et al, 1999).
Standardised incidence ratios were above unity for a few
additional cancer types (i.e. stomach, rectum, and ovary), but
corresponding CI were broad, due to the relatively small number
of cases observed.
No reduction in the SIR of NADCs emerged in Italy after the
introduction of HAART. Our present study is based, however, on
too short a period after HAART to allow any conclusion.
The validity of cohorts defined by AIDS diagnosis, as in record
linkage studies, to estimate risks of NADCs before AIDS has been
questioned (Goedert et al, 1998; International Collaboration on
HIV and Cancer, 2000). Li et al (2002), however, have recently
demonstrated that in Australia one cohort based on AIDS
diagnosis and two based on HIV diagnosis provided consistent
SIRs for the 10 commonest NADCs.
Since a large number of NADCs occurs before AIDS, the major
strength of such methodology is represented by the access to a
large number of person-years of observation both before and after
AIDS (Franceschi et al, 1998b; Goedert et al, 1998). The number of
PWHA and of cancer diagnoses may be underestimated on
account of incompleteness of reporting to either AIDS or CRs or
of missed linkages. However, the completeness of RAIDS and
Italian CRs had been shown to be satisfactory and the linkage
procedures we used had been validated (Conti et al, 1997; Ajdacic-
Gross et al, 2001; Dal Maso et al, 2001a). The problem of migration
of PWHA out of CR areas should be less severe in Italy than
elsewhere, as population mobility is comparatively low and HIV
and cancer treatments are available free of charge in all Italian
regions (Franceschi et al, 1998b). As already reported (Biggar et al,
1996), SIRs for all cancer sites or types are exaggerated in the
Table 3 Observed cases (Obs) of selected cancers, SIR and corresponding 95% CI among people with HIV or AIDS by gender, age group, and HIV
exposure category, Italy, 1985–1998
Gender Age group
HIV exposure
category
Men Women 15–34 35–69 IDU Other
ICD10–cancer
type or site Obs
SIR
(95% CI) Obs
SIR
(95% CI) Obs
SIR
(95% CI) Obs
SIR
(95% CI) Obs
SIR
(95% CI) Obs
SIR
(95% CI)
C46: KS 483 1696 42 2717 228 1218 297 2628 115 557 410
a 4369
(1548–1854) (1957–3675) (1065–1387) (2337–2945) (460–669) (3956–
4813)
C82–C85: NHL 350 321 99 538 268 417 181 286 247 335 202 376
(288–356) (437–655) (369–470) (246–331) (294–379) (326–432)
C53: ICC — — 18 21.8 8 23.4 10 20.7 11 24.0 7 19.1
— (12.9–34.6) (10.0–46.4) (9.9–38.2) (11.9–43.1) (7.6–39.6)
C21: anus 5 35.1 1 27.6 1 31.3 5 34.1 2 33.6 4
b 33.6
(11.1–82.5) (0.0–158.3) (0.0–179.3) (10.8–80.2) (3.2–123.6) (8.7–86.8)
C33, C34: trachea and lung 19 2.2 3 8.7 6 19.4 16 1.8 11 9.4 11 1.4
(1.3–3.4) (1.6–25.9) (7.0–42.4) (1.0–3.0) (4.6–16.8) (0.7–2.5)
C44: skin 13 1.7 1 0.7 0 0 14 1.9 1 0.4 13 2.0
(0.9–2.8) (0.0–4.0) — (1.0–3.1) (0.0–2.0) (1.1–3.5)
C70–C72: brain 8 3.8 3 8.5 6 6.4 5 3.2 8 6.7 3 2.3
(1.6–7.4) (1.6–25.3) (2.3–14.1) (1.0–7.6) (2.9–13.2) (0.4–6.9)
C81: Hodgkin’s disease 36 16.7 9 14.6 33 17.9 12 12.9 34 18.1 11 12.3
(11.7–23.1) (6.6–27.9) (12.3–25.2) (6.7–22.7) (12.5–25.3) (6.1–22.1)
C91–C95: leukaemias 12 5.7 1 2.9 8 8.4 5 3.4 5 4.3 8 6.3
(2.9–10.1) (0.0–16.7) (3.6–16.7) (1.1–7.9) (1.3–10.0) (2.7–12.6)
All non-AIDS defining Cancers 135 2.2 35 2.5 74 4.6 96 1.6 87 3.6 83 1.7
(1.9–2.7) (1.7–3.4) (3.6–5.8) (1.3–2.0) (2.9–4.4) (1.3–2.1)
SIR=Standardized Incidence Ratios; CI=Confidence Intervals; KS=Kaposi’s Sacroma; NHL=Non-Hodgkin Lymphoma; ICC=Invasive Cervical Cancer. IDU¼Intravenous drug user.
a310 cases among homosexual and bisexual men, SIR¼6066, 95% CI: 5409–6780.
bThree cases among homosexual and bisexual men, SIR¼56.4, 95% CI: 10.6–167.0.
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medical surveillance and some cancers would have been otherwise
found later. Our present SIRs in the post-AIDS period are therefore
underestimates and this hampers the evaluation of trends in
cancer risk by immune status. Cancer excesses were also found,
however, prior to AIDS diagnosis, for ICC, cancer of the anus,
and HD.
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APPENDIX
Cancer and AIDS Registry Linkage Study: Diego Serraino (IRCCS
‘L. Spallanzani’, Rome); Gary Clifford (IARC Lyon, France);
Eugenio Paci (Registro Tumori Toscano, Florence); Rosa Vattiato
(Registro Tumori della Romagna, Forlı `); Anna Rita Fiore (Registro
Tumori del Veneto, Padova); Silvia Patriarca (Registro Tumori
Piemonte, Torino); Claudia Casella (Registro Tumori Ligure,
Genoa); Paolo Contiero, Giovanna Tagliabue (Registro Tumori
Lombardia – Provincia di Varese); Maria Elisa Artioli, Katia Valla
(Registro Tumori della Provincia di Modena); Vincenzo De Lisi,
Lidia Serventi (Registro Tumori della Provincia di Parma);
Francesco La Rosa, Fabrizio Stracci (Registro Tumori Umbro);
Stefano Ferretti, Anna Rita Lombardi (Registro Tumori della
Provincia di Ferrara); Massimiliano Oggiano, Amelia Sechi
(Registro Tumori della Provincia di Sassari); Silva Franchini,
Maria Gentilini (Registro Tumori della Provincia di Trento); Ettore
Conti, Valerio Ramazzotti (Registro Tumori di Popolazione della
Provincia di Latina); Adriano Giacomin, Lucia Preto (Registro
Tumori della Provincia di Biella); Gianni Vicario, Loris Zanier
(Registro dei Tumori del Friuli-Venezia Giulia); Francesco Bellu `,
Fabio Vittadello (Registro Tumori dell’Alto Adige); Susanna
Vitarelli, Franco Pannelli (Registro Tumori Provincia di Macerata,
Camerino); Rosario Tumino, Lorenzo Gafa ` (Registro Tumori
Ragusa); Maurizio Montella, Mario Fusco (Registro Tumori della
Provincia di Napoli); Stefano Boros, Patrizio Pezzotti (Istituto
Superiore di Sanita `, Roma).
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